Q-omics provides the consensus-scored MOV10 profile across patient tissues and cancer cell-line models. MOV10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MOV10 is differentially expressed in 17, with the highest sampling consensus in LIHC. Additionally, MOV10 protein abundance shows 19,770 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where MOV10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MOV10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MOV10 survival associations across molecular data types. MOV10 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MOV10 RNA expression–survival associations across cancer types. High MOV10 expression shows unfavorable associations in KIRC, LIHC, UCEC, ACC, KICH and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MOV10 RNA expression.
This table summarizes MOV10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MOV10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MOV10 shows lower tumor expression in KICH and higher tumor expression in LIHC, BLCA, LUAD, KIRC and STAD. The LIHC box plot shows higher MOV10 RNA expression in tumor versus normal tissue (log2 FC = +1.298, t-test p < 0.001).
This table shows molecular features associated with MOV10 in patient tissues and cancer cell lines. In patient samples, MOV10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MOV10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
